These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 27703346

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.
    Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.
    Respir Res; 2018 Oct 05; 19(1):196. PubMed ID: 30290801
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.
    Int J Chron Obstruct Pulmon Dis; 2016 Oct 05; 11():1921-8. PubMed ID: 27574416
    [Abstract] [Full Text] [Related]

  • 6. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice.
    Kaplan AG.
    Int J Chron Obstruct Pulmon Dis; 2015 Oct 05; 10():2535-48. PubMed ID: 26648711
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study.
    Morjaria JB, Rigby A, Morice AH.
    Lung; 2017 Jun 05; 195(3):281-288. PubMed ID: 28255905
    [Abstract] [Full Text] [Related]

  • 10. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
    Stynes G, Svedsater H, Wex J, Lettis S, Leather D, Castelnuovo E, Detry M, Berry S.
    Respir Res; 2015 Feb 15; 16(1):25. PubMed ID: 25849223
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA.
    Pulm Pharmacol Ther; 2008 Feb 15; 21(3):540-50. PubMed ID: 18280761
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis.
    Oba Y, Lone NA.
    Int J Chron Obstruct Pulmon Dis; 2014 Feb 15; 9():469-79. PubMed ID: 24872685
    [Abstract] [Full Text] [Related]

  • 14. Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
    Devereux G, Cotton S, Barnes P, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Fielding S, Gompertz S, Haughney J, Lee AJ, McCormack K, McPherson G, Morice A, Norrie J, Sullivan A, Wilson A, Price D.
    Trials; 2015 Jun 10; 16():267. PubMed ID: 26058585
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of Inhaled Corticosteroids on Bronchial Inflammation and Pulmonary Function in Chronic Obstructive Pulmonary Disease with Moderate Obstruction.
    Toczyska I, Zwolińska E, Chcialowski A.
    Adv Exp Med Biol; 2018 Jun 10; 1047():41-52. PubMed ID: 29181828
    [Abstract] [Full Text] [Related]

  • 18. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD.
    Mathioudakis AG, Bikov A, Foden P, Lahousse L, Brusselle G, Singh D, Vestbo J.
    Eur Respir J; 2020 May 10; 55(5):. PubMed ID: 32108044
    [Abstract] [Full Text] [Related]

  • 19. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 May 10; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 20. The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
    Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.
    Int J Chron Obstruct Pulmon Dis; 2015 May 10; 10():2431-8. PubMed ID: 26648706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.